Biological heterogeneity of small cell lung cancer
- PMID: 2996148
Biological heterogeneity of small cell lung cancer
Abstract
Over the past 20 years considerable advances have been made in the characterization of the biologic properties of small cell lung cancer. The recognition that this histologic type of lung cancer, in contrast to the other major types of lung cancer, is highly sensitive to both chemotherapy and radiation therapy lead to significant improvements in the overall survival of patients with this disease. However, in spite of the initial major advances in therapy, overall results and survival have remained unchanged over the past 5 years. The majority of patients, although they will demonstrate an initial response to cytotoxic therapy, will ultimately die of their disease due to the development of drug resistance. Whether this development of drug resistance within a tumor cell represents the emergence of resistant clones of cells present at diagnosis, or a change within the cells exposed to cytotoxic therapy that renders them resistant to further therapy remains to be determined. The development of laboratory techniques that facilitate the culture and establishment of SCLC cell lines has greatly improved our understanding of the biology of SCLC, in addition to providing useful models for studies of mechanisms of drug resistance and metabolism. The ease of establishment of SCLC cell lines in defined medium suggests that these cells secrete "autocrine growth factors" essential for their growth in vitro. The characterization of these factors may provide an alternative means for treating this tumor in vivo. Moreover, by developing specific culture media for other types of lung cancer, similar advances in our knowledge of these tumors will occur. Although the growth of SCLC cells in a clonogenic assay may be of value in chemotherapy selection, the established cell lines provide a model for studying mechanisms of drug and radiation sensitivity; and drug metabolism. The recognition that SCLC cell lines have elevated levels of L-dopa decarboxylase has lead to the development of specific agents that may alter the growth of these cells through inhibition of polyamine synthesis. Such specifically designed therapy may become important in the future therapy of these patients. The establishment of cell lines has clearly indicated the considerable heterogeneity that exists in SCLC.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Small cell lung cancer: etiology, biology, clinical features, staging, and treatment.Curr Probl Cancer. 1993 Mar-Apr;17(2):69-141. doi: 10.1016/0147-0272(93)90010-y. Curr Probl Cancer. 1993. PMID: 8395998 Review.
-
Small cell lung cancer cell line derived from a primary tumor with a characteristic deletion of 3p.Cancer Res. 1987 Apr 15;47(8):2148-55. Cancer Res. 1987. PMID: 3030544
-
Additive and differential biological activity of alpha-interferon A, difluoromethylornithine, and their combination on established human lung cancer cell lines.Cancer Res. 1986 Jul;46(7):3413-9. Cancer Res. 1986. PMID: 3085922
-
Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties.Cancer Res. 1985 Jun;45(6):2924-30. Cancer Res. 1985. PMID: 2985258
-
Lung cancer biology.Semin Oncol. 1988 Jun;15(3):199-214. Semin Oncol. 1988. PMID: 3289122 Review.
Cited by
-
Tetanus toxin as a marker for small-cell lung cancer cell lines.J Cancer Res Clin Oncol. 1989;115(6):537-42. doi: 10.1007/BF00391354. J Cancer Res Clin Oncol. 1989. PMID: 2558117 Free PMC article.
-
The role of ifosfamide and cyclophosphamide in the multi-modality treatment after surgery for cure for small-cell bronchial carcinomas (SCLC).Med Oncol Tumor Pharmacother. 1989;6(2):143-9. doi: 10.1007/BF02985237. Med Oncol Tumor Pharmacother. 1989. PMID: 2545979 Clinical Trial.
-
Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer.Br J Cancer. 2009 Jun 16;100(12):1949-56. doi: 10.1038/sj.bjc.6605068. Epub 2009 May 19. Br J Cancer. 2009. PMID: 19455144 Free PMC article.
-
Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes.Transl Lung Cancer Res. 2018 Feb;7(1):32-49. doi: 10.21037/tlcr.2018.02.02. Transl Lung Cancer Res. 2018. PMID: 29535911 Free PMC article.
-
In vitro effects of substance P analogue [D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P on human tumour and normal cell growth.Br J Cancer. 1992 Mar;65(3):388-92. doi: 10.1038/bjc.1992.78. Br J Cancer. 1992. PMID: 1373071 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous